AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$184.96
-2.76 (-1.47%)
▼
5d:
+1.34%
30d:
-8.08%
90d:
-9.56%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AZN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: AZN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$229.54
Based on 9.3% avg growth
INTRINSIC VALUE TODAY
$142.53
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $184.96, which is considered slightly low relative to its 30-day fair value range of $184.15 to $201.30. From a valuation perspective, the stock is trading at a premium (Forward PE: 31.3) compared to its historical average (28.2). At these levels, the market is pricing in 3.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is currently testing key support at $180.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $224.49 (+21.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is currently testing key support at $180.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $224.49 (+21.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$184.15 -
$201.30
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.4% below Wall St target ($224.49)
- NEUTRAL: Market pricing in 3.5% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$184.15 -
$201.30
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$180.00
Resistance Level
$187.78
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.33
Wall Street Target
$224.49
(+21.4%)
Revenue Growth (YoY)
12.5%
Earnings Growth (YoY)
5.3%
Profit Margin
17.2%
Valuation Premium vs History
+3.5% premium
PE vs Historical
31.3 vs 28.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.5%
(market-implied from PE analysis)
1-Year Target
$191.43
(+4%)
2-Year Target
$198.13
(+7%)
3-Year Target
$205.07
(+11%)
3-Yr Target (if PE normalizes)
(PE: 31→28)
PE COMPRESSION
$184.57
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.3, Growth: 14.6%)
$278.51
(+51%)
Base:
(SPY PE: 22.0, Growth: 14.6%)
$195.92
(+6%)
Bear:
(PE: 18.7, Growth: 14.6%)
$166.53
(-10%)
📈
Valuation based on Current Earnings
Trailing PE: 27.90 | Current EPS (TTM): $6.65
Bull Case
$181.15
(-2%)
Analyst growth -11.2%, PE expands to 30.7
Base Case
$164.68
(-11%)
Market implied -11.2%, PE stable at 27.9
Bear Case
$126.15
(-32%)
Severe decline -20.0%, PE contracts to 23.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 14, 2026 10:50 PM ET
Data refreshes hourly during market hours. Next update: 11:50 PM
Data refreshes hourly during market hours. Next update: 11:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 62 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 60 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$217 | 63 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$252 | 61 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 57 HOLD |
